

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-55 (Cancelled)

56. (New) An antibody which specifically binds to a protein comprising the amino acid sequence of SEQ ID NO:1.

57. (New) An antibody which specifically binds to a protein comprising the amino acid sequence of SEQ ID NO:2.

58. (New) An antibody which specifically binds to a rapamycin effector protein.

59. (New) The antibody of claim 58, wherein the rapamycin effector protein is about 125 kD.

60. (New) The antibody of claim 58, wherein the rapamycin effector protein is about 148 kD.

61. (New) The antibody of claim 58, wherein the rapamycin effector protein is about 208 kD.

62. (New) The antibody of claim 58, wherein the rapamycin effector protein is about 210 kD.

63. (New) An antibody which specifically binds a protein which is substantially similar to a rapamycin effector protein.

64. (New) An antibody to an amino acid sequence encoded by plasmid comprising a DNA sequence encoding at least a portion of a rapamycin effector protein.

PATENT
Customer No. 22,852
Attorney Docket No. 08702.0007-02000

65. (New) The antibody of claim 9, where the plasmid is pUC19-Sep1 (ATCC Accession No.: 69756).

66. (New) The antibody of claim 9, where the plasmid is pUC18-Sep23 (ATCC Accession No.: 697563).

67. (New) The antibody of claim 9, where the plasmid is pUC18-Sep45 (ATCC Accession No.: 69754).

68. (New) The antibody of claim 9, where the plasmid is pUC19-Sep1-5 (ATCC Accession No.: 69829).

69. (New) The antibody of claim 9, where the plasmid is pGEX-Sep45 (ATCC Accession No.: 69755).

70. (New) An antibody to an isolated protein where the protein is made by a process comprising the steps of:

- (a) providing a sample of mammalian cellular material;
- (b) preparing an extract of the cellular material comprising cell membrane proteins;
- (c) contacting the extract with an affinity reagent comprising a complex of:

(i) rapamycin and

(ii) FKBP12

under conditions which permit materials capable of specifically binding to the affinity reagent to bind thereto;

(d) separating materials which do not bind to the affinity reagent from the affinity reagent and the materials bound thereto;

(e) dissociating the materials bound to the affinity reagent therefrom; and

(f) separating the protein based on its molecular weight from the other materials dissociated from the affinity reagent.

71. (New) The antibody of claim 70, wherein the isolated protein has a molecular weight of about 210 kD.

72. (New) The antibody of claim 70, wherein the isolated protein has a molecular weight of about 148 kD.

73. (New) The antibody of claim 70, wherein the isolated protein has a molecular weight of about 125 kD.

74. (New) An isolated antibody which specifically binds to a protein comprising amino acids 1987 to 2146 of SEQ ID NO:1

75. (New) An isolated antibody which specifically binds to a protein comprising amino acids 741 to 2549 of SEQ ID NO:1.

76. (New) The isolated antibody of claim 74 or 75, which specifically binds to an FKBP/rapamycin-binding (FRB) domain.

77. (New) The isolated antibody of claim 74, which does not substantially cross-react with a protein which is less than 90% homologous to amino acids 1987 to 2146 of SEQ ID NO:1.

78. (New) The isolated antibody of claim 77, which does not substantially cross-react with a protein which is less than 95% homologous to amino acids 1987 to 2146 of SEQ ID NO:1.

79. (New) The isolated antibody of claim 75, which does not substantially cross-react with a protein which is less than 90% homologous to amino acids 741 to 2549 of SEQ ID NO:1.

80. (New) The isolated antibody of claim 79, which does not substantially cross-react with a protein which is less than 95% homologous to amino acids 741 to 2549 of SEQ ID NO:1.

81. (New) A purified preparation of an antibody, or an antigen binding fragment thereof, which is specifically immunoreactive with a protein comprising amino acids 1987 to 2146 of SEQ ID NO:1.

82. (New) A purified preparation of an antibody, or an antigen binding fragment thereof, which is specifically immunoreactive with a protein comprising amino acids 741 to 2549 of SEQ ID NO:1.

83. (New) A polyclonal antibody preparation comprising antibodies specifically immunoreactive with a protein comprising amino acids 1987 to 2146 of SEQ ID NO:1.

84. (New) A polyclonal antibody preparation comprising antibodies specifically immunoreactive with a protein comprising amino acids 741 to 2549 of SEQ ID NO:1.

85. (New) A monoclonal antibody composition comprising a monoclonal antibody, or an antigen binding fragment thereof, which is specifically immunoreactive

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

with a protein having an amino acid sequence at least 90 percent homologous to amino acids 1987 to 2146 of SEQ ID NO:1.

86. (New) A monoclonal antibody composition comprising a monoclonal antibody, or an antigen binding fragment thereof, which is specifically immunoreactive with a protein having an amino acid sequence at least 90 percent homologous to amino acids 741 to 2549 of SEQ ID NO:1.

87. (New) The preparation of claim 81, which is specifically immunoreactive with a protein having an amino acid sequence at least 90 percent homologous amino acids 1987 to 2146 of SEQ ID NO:1.

88. (New) The preparation of claim 87, which is specifically immunoreactive with a protein having an amino acid sequence at least 95 percent homologous amino acids 1987 to 2146 of SEQ ID NO:1.

89. (New) The preparation of claim 82, which is specifically immunoreactive with a protein having an amino acid sequence at least 90 percent homologous to amino acids 741 to 2549 of SEQ ID NO:1.

90. (New) The preparation of claim 89, which is specifically immunoreactive with a protein having an amino acid sequence at least 95 percent homologous to amino acids 741 to 2549 of SEQ ID NO:1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com